-
Health todayCancer refines
GLP-1 receptor agonists and lung cancer in type 2 diabetes with pulmonary nodules
GLP-1 receptor agonists were linked to fewer lung cancers than metformin, but genetic and SGLT2 inhibitor comparisons gave no support.
Peer-reviewed -
Tomorrow's worldInnovation in treatment new
Trevogrumab, with or without garetosmab, against muscle loss on semaglutide in obesity
A phase 2 trial in 975 adults with obesity tested GDF8 and activin A antibodies against semaglutide-related lean mass loss.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes with obesity
In Clalit's medical records, liraglutide and dulaglutide matched SGLT-2 inhibitors on weight loss but lowered HbA1c more.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
US cardiovascular risk factors 1999-2023 show rising obesity and diabetes, less smoking
Across 11 NHANES cycles, obesity rose to 57.2% and diabetes to 12.7%, while blood pressure control fell to 21.5%.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Clinical obesity framework classes most BMI-defined obesity at age 46 as pre-clinical
In 6,978 British Cohort Study members aged 46, only 31.4% with BMI-defined obesity met clinical obesity criteria.
Peer-reviewed -
Data, models and systemsValue in health new
Vitamin D for US adults with prediabetes saved costs in a lifetime microsimulation model
In a simulated US cohort with prediabetes, daily vitamin D3 lowered lifetime costs by $3208 per person and added 0.12 QALYs, assuming the 15% cut in diabetes risk seen in pooled trials.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists and lower heart failure admission or death in diabetic HFrEF
In diabetic HFrEF, GLP-1 RA use had a 12-month risk ratio of 0.58 for heart failure admission or death.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Bariatric procedures linked to fewer diabetes complications and deaths than obesity drugs
Bariatric procedures were linked to lower 5-year nephropathy, retinopathy, cardiovascular events and deaths than obesity management medications.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Diagnosed diabetes in Korea rose with age and year, with higher odds in two birth cohorts
In 3.2 million Korean survey respondents, reported diagnosed diabetes rose with age and year and was higher in two cohorts.
Peer-reviewed -
Behavioural scienceAdherence and persistence refines
Semaglutide for obesity: two-thirds of new Wegovy users stopped within a year
Of 34,309 Clalit members without diabetes starting Wegovy in 2025, 67.6% had stopped by one year.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists' share of US prescriptions rose 7% from June to September 2026
Anti-obesity GLP-1 prescribing rose 12.2% in mid-2026, with the largest monthly rise in July, when a Medicare cost-cutting programme began.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Semaglutide for weight management and use of other prescribed medicines in Denmark
In 189,392 Danish semaglutide initiators, antiasthmatic use fell below trend (RR 0.82) while anxiolytic use rose (RR 1.16).
Peer-reviewed